Armata Pharmaceuticals Files 8-K: Material Agreement & Financial Obligation
Ticker: ARMP · Form: 8-K · Filed: Mar 12, 2025 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, regulation-fd
TL;DR
Armata Pharma just signed a big deal and took on debt. Details TBD.
AI Summary
On March 12, 2025, Armata Pharmaceuticals, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The filing indicates a Regulation FD Disclosure and includes financial statements and exhibits. Specific details of the agreement and financial obligation are not provided in this excerpt.
Why It Matters
This filing signals a significant development for Armata Pharmaceuticals, potentially involving new financing, partnerships, or debt, which could impact its operational capacity and future growth.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, which inherently carries financial risk for the company.
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- March 12, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement Armata Pharmaceuticals entered into?
The filing states that Armata Pharmaceuticals, Inc. entered into a material definitive agreement on March 12, 2025, but the specific details of this agreement are not provided in this excerpt.
What is the direct financial obligation incurred by Armata Pharmaceuticals?
Armata Pharmaceuticals, Inc. incurred a direct financial obligation on March 12, 2025, as reported in the 8-K filing, though the specifics of this obligation are not detailed in the provided text.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure indicates that the company is making public information that could be considered material, ensuring fair disclosure to all investors.
What are the previous names of Armata Pharmaceuticals, Inc.?
Armata Pharmaceuticals, Inc. was formerly known as AmpliPhi Biosciences Corp, with a name change on February 22, 2013, and prior to that, it was known as TARGETED GENETICS CORP /WA/, with a name change on March 31, 1994.
What is Armata Pharmaceuticals' fiscal year end?
Armata Pharmaceuticals, Inc.'s fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 12, 2025 regarding Armata Pharmaceuticals, Inc. (ARMP).